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ABSTRACT 
Overexpression of the Epidermal Growth Factor Receptor (EGFR) by cancer cells is associated with a poor prognosis for 
the patient. For several decades, therapies targeting EGFR have been designed, including the use of monoclonal 
antibodies and small molecule tyrosine kinase inhibitors. The use of these molecules had good clinical results, although 
its efficiency (and specificity) is still far from being optimal.  
In this paper, we present a new approach for a possible new cancer therapy targeting EGFR and using low intensity 
280nm light. The influence of 280nm UVB illumination on cancer cells stimulated with 2nM of EGF was followed by 
time-lapse confocal microscopy. The 280nm illumination of the cancer cells blocks EGFR activation, inhibiting EGFR 
internalization and cell migration thus inhibiting the transition to the metastatic phenotype. Exposure time is a very 
important factor. The higher the illumination time the more significant differences were observed: 280nm light delayed 
or completely halted EGFR activation in the cell membrane, mainly at the cell junction level, and delayed or halted 
EGFR endocytic internalization, filopodia formation and cell migration.  
Keywords: Epidermal Growth Factor Receptor, Activation, Arrest, EGFR, EGF, Cancer cells, Photonic Therapy, Cell 
Migration, Filopodia. 
1. INTRODUCTION
Solid tumor growth is associated to several genetic events that influence cell differentiation, proliferation, survival and 
mobility1. The activation of the pro-oncogene encoding for the epidermal growth factor receptor (EGFR) confers 
advantages to the cancer cells promoting survival and proliferation1. A high level of EGFR expression by cancer cells is 
associated with a poor prognosis for the patient. EGFR is overexpressed in most solid tumors, such as, breast, head and 
neck, non-small cell lung cancer and prostate cancer2,3. During the past decades several therapies targeting EGFR have 
been designed using monoclonal antibodies4-9 and small molecule tyrosine kinase inhibitors5,8,10-13. These approaches 
have achieved some good results, although its efficiency is still far from being optimal14,15. 
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The development of an efficient anti-cancer therapy, which can be used alone or as a complementary technique, is of 
outmost importance. Photonics, more precisely biophotonics, is a promising field in this regard. In 1903, Niels Ryberg 
was awarded with the Nobel Prize in Medicine and Physiology due to outstanding and extensive use of UV light in the 
treatment of skin diseases. Currently, medical treatments using UV light are quite common. UV light has been applied 
for the treatment of skin diseases like psoriasis16,17. Additionally, UV light is used to treat cutaneous T-cell 
lymphoma18,19, a therapy approved by the Food and Drug Administration (FDA). The use of photons for cancer treatment 
is not a novel concept but new approaches are being explored. It is known that UVB light affects proteins. UVB 
excitation of tryptophan (Trp) and tyrosine (Tyr) side chains leads to the reduction of disulphide bridges bridges in a 
protein20,21. UV excitation of Trp or Tyr residues results in photoionization and generation of solvated electrons21,22. The 
solvated electrons undergo fast geminate recombination with their parent molecule, or they can be captured by 
electrophilic species like molecular oxygen, H3O+ (at low pH), and cysteines (schemes 1, 2 and 3, respectively): 
The electron captured by the cysteine (scheme 3) leads to the breakage of the SS bridge (schemes 4 and 5). EGFR is the 
perfect target for this approach, as it is rich in disulphide bridges in close spatial proximity of aromatic residues: it has 25 
disulphide bridges, 6 Trp residues, 16 Tyr residues and 18 Phe residues per chain. This feature makes EGFR extremely 
susceptible to 3D conformational changes induced by UV light. The induced conformational changes will prevent the 
correct binding to its ligands, inhibiting its function. Olsen et al.23 demonstrated that laser pulsed UVB (280nm) 
excitation of two skin-derived tumor cell lines overexpressing EGFR, A431 (human epidermoid carcinoma cells) and 
Cal39 (derived from human vulva squamous cell carcinoma cells), with an irradiance level of 0.35 W.m-2 leads to the 
inhibition of the EGF receptor and of key downstream molecules such as AKT1 and ERK1/2 involved in the RTK-
catalyzed signaling cascade, leading to cell apoptosis. Correia et al.24 demonstrated that illumination of EGFR with UVB 
light (280 nm) at an irradiance level of 0.08 W.m-2 induced structural changes in the receptor affecting the EGF binding 
site. More recently, Botelho et al.25 demonstrated that the illumination of pulmonary cancer cells with UVB light using 
an irradiance of 0.27 W.m-2 maintains the integrity of the confluent cancer cell monolayer upon EGF activation for a 
longer period of time in comparison with non-illuminated cancer cells.  
The present study aims at evaluating the influence of 280nm illumination time on cancer cell migration, using a fluency 
of 1.18 W.m-2. This value is lower than the highest total irradiance of sunlight in the UVB region is ~0.78W.m-2 in the 
range 280-315nm26, which is, and 1.75W.m-2 at 39ºN in summer and 0.4 W/m2 in December  at wavelengths below 
313nm27. 
2. MATERIAL AND METHODS
2.1. Cell line  
The cell line used in this study was the lung carcinoma cell line with GFP-tagged EGFR (A549-GFP-tagged SH2 
biosensor cell line from Sigma-Aldrich, 86012804), which expresses EGFR tagged with GFP. The EGFR gene was 
endogenously tagged with a Green Fluorescent Protein gene (GFP) using CompoZr® Zinc Finger Nuclease technology. 
Cells were seeded into µ-Slide 4 wells (3x104 cells/cm2) in Dulbecco's Modified Eagle Medium (DMEM) with 2 mM 
glutamine, 1 µg/mL puromycin (complete medium) and 10% of fetal bovine serum (FBS). The cancer cells were kept at 
37ºC in a 5% CO2 atmosphere in complete medium, 10% of FBS. At the beginning of each experiment the culture 
medium was replaced by DMEM containing 2% of FBS and EGF (0 nM and 2 nM). 
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280nm illumination was provided by the Xe arc lamp (LX 300UV) of an ISS Chronos BH steady state fluorometer with 
a computer controlled monochromator. The light was focused onto an optical fiber with a core diameter of 150μm. Light 
was shaped to a 1cm diameter circular beam and passed centrally through the excitation volume. The cells were 
illuminated for 15min and 45min with 280nm light at 1.18 W.m-2 (0.093mW, 18A, slit width 16nm). The solution was 
kept at room temperature (~22ºC) during illumination.  
2.3. Confocal Laser Scanning Microscopy (CLSM) 
The morphology and the mobility of non-illuminated versus 280nm illuminated cells were monitored using CLSM. All 
experiments were carried out at 37ºC using a heat chamber coupled onto the Zeiss-LSM780. The cell medium containing 
2% FBS was supplemented with 2nM EGF when appropriate. The addition of EGF was considered the time zero for the 
time-lapse experiments 
3. RESULTS AND DISCUSSION
Cancers originated in epithelial cells (carcinomas) represent about 85% of all cancers. According to the literature, at least 
33-50% of human carcinomas have a significant overexpression of EGFR28–30. As previously mentioned, the success of
the existing anti-cancer therapies targeting EGFR is still far from optimal. Therefore, in this paper we describe a new
method to target EGFR, disrupting its structure and function, which can be used as a complementary technique to the
existing ones. The beneficial effects of UVB light are widely described in the literature, from the stimulation of vitamin
D production to the treatment of skin diseases like, psoriasis, vitiligo, atopic dermatitis and localized scleroderma31-33.
The ErbB family of receptors, which includes EGFR, influences cell survival, adhesion, migration, proliferation and 
differentiation28. Thus, it was expected that stimulation of cells overexpressing EGFR with 2nM of EGF would result in 
high cell migration and EGFR dimerization and consequent receptor activation. Cell morphology and behavior were 
followed by time-lapse using confocal microscopy. 
The first step of this study was to evaluate the morphology and behavior of the cells for a period of 60 minutes without 
any EGF stimulation or UVB light illumination. As it can be seen in Figure 1, when non-activated and non-illuminated 
cells are monitored for 60 minutes there are no significant changes on cell morphology and it is possible to observe the 
early stage of cell migration (Figure 1 A5). When these cells were stimulated with 2nM of EGF, a significant number of 
events take place as it can be seen in Figure 2. The activation of EGFR receptors is observable 6 min after stimulation by 
EGF (Figure 2 A2), especially in cell junctions, followed by the internalization through endocytosis, which is visible by 
the appearance of bright fluorescent dots inside the cell 14 min after EGF stimulation. This event is even more evident 
28 min after EGF stimulation (Figure 2 A4). Finally, after 60 min, the disintegration of the cell monolayer is evident, as 
well as filopodia formation and internalization of the EGF-EGFR complexes. These results are in agreement with 
previous studies regarding the intracellular trafficking of EGFR34, showing that EGFR signaling continues after receptor 
internalization. The effects observed are consistent with the acquisition of a metastatic phenotype which is correlated 
with the epithelial-mesenchymal transition (EMT)35-38. EMT is associated with  E-cadherin downregulation affecting the 
integrity of the adherent junctions39. EGFR signaling may lead to the loss of cell-cell adhesion through E-cadherin 
downregulation. This may be due to the destabilization of E-cadherin/catenin adhesive complexes, E-cadherin 
endocytosis or downregulation of E-cadherin expression. Additionally, EMT is accompanied by downregulation of P-
cadherin and cadherin 6, as well as the appearance of N-cadherin, cadherin 11 and R-cadherin. Therefore, E-cadherin can 
be considered an invasiveness suppressor gene39. 
2.2. Illumination setup (280 nm) 
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Figure 1 – Confocal laser scanning microscopy images of lung carcinoma cells. A1 – Cell monolayer morphology before 
EGF addition; A2-5 – Morphology of cell monolayer after 6, 14, 28 and 60min, respectively (EGF has not been added to 
the medium).  
Figure 2 - Confocal laser scanning microscopy images of lung carcinoma cells. A1 – Cell monolayer morphology before 
EGF addition; A2-5 – Morphology of cell monolayer after 6, 14, 28 and 60min exposure to 2nM of EGF, respectively; A6 
– 3D image of the cell monolayer after 90min of exposure to 2nM of EGF. The scale bar represents the depth in the Z axis.
The second step of this study was to evaluate the effect of 280nm light on non-stimulated cells. For that, the cells were 
illuminated with 280nm at an irradiance level of 1.18 W.m-2 using two different exposures time, 15 and 45min. As can 
be seen in Figures 3 and 4, no significant changes on the morphology of the cells were observed from time 0 to time 
60min after EGF addition, in either case. The illumination of the non-stimulated cells seems to delay cell migration when 
the cells were illuminated with 280nm light for 15 or 45 min, as can be observed when comparing the 60min panels 
(Figures 3 and 4, panelsA5) with the respective data displayed in Figure 1 A5.  
Figure 3 - Confocal laser scanning microscopy images of lung carcinoma cells. A1 – Cell monolayer morphology before 
EGF addition; A2-5 – Morphology of cell monolayer after 6, 14, 28 and 60min. 280nm illumination has been carried out 
with an irradiance of 1.18 W.m-2 for 15min. No EGF has been added to the cells in this experiment. 
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Figure 4 - Confocal laser scanning microscopy images of lung carcinoma cells. A1 – Cell monolayer morphology before 
EGF addition; A2-5 – Morphology of cell monolayer after 6, 14, 28 and 60min. 280nm illumination has been carried out 
with an irradiance of 1.18 W.m-2 for 45min. No EGF has been added to the cells in this experiment. 
The final goal of this new biophotonic approach was to delay migration of EGF-stimulated cells. Time-lapse confocal 
microscopy was used to evaluate the influence of 280nm light on cancer cells stimulated with 2nM of EGF. As observed 
in Figure 5, when the stimulated cells were exposed to 280nm light for 15 min, EGFR activation is only observed 14-
28min after EGF addition. The internalization of these complexes is more evident at 60 min. The formation of filopodia 
is scarce and no evident cell migration is observed. The internalization of EGFR/EGF complexes can be observed and is 
displayed as a 3D image (Figure 5 A6) obtained 90min after EGF stimulation but at a lower extent than in non-
illuminated cells.  
Figure 5 - Confocal laser scanning microscopy images of lung carcinoma cells. A1 – Cell monolayer morphology before 
EGF addition; A2-5 – Morphology of cell monolayer after 6, 14, 28 and 60min exposure to 2nM of EGF, respectively. 
Prior to EGF addition, the cells have been illuminated with an irradiance of 1.18 W.m-2 for 15min; A6 – 3D image of the 
cell monolayer after 90min of exposure to 2nM of EGF. Prior to EGF addition, the cells have been illuminated with 280nm 
at an irradiance of 1.18 W.m-2 for 15min. 
The delayed activation of EGFR by EGF and consequent receptor internalization is even more evident in cells that were 
illuminated for a longer period of time (45 min) prior to EGF stimulation. As it can be observed in Figure 6 A4, the 
extent of EGFR activation observed 28min after EGF stimulation in cells previously illuminated for 45min is less than 
the respective level of activation observed in stimulated but non-illuminated cells (Figure 2 A4) and less than that of 
cells illuminated for only 15 min (Figure 3 A4). This is even more clear when looking at the confocal images obtained 60 
min after EGF stimulation. The integrity of the cell monolayer is practically intact in cells previously illuminated for 
45min with 280nm light at 1.18 W.m-2.  
Proc. of SPIE Vol. 10048  100480R-5
Downloaded From: https://www.spiedigitallibrary.org/conference-proceedings-of-spie on 1/18/2018 Terms of Use: https://www.spiedigitallibrary.org/terms-of-use
OW.m-2; Omin
1.18W.m-2; 15min.
1.18W.m-2; 45min
Figure 6 - Confocal laser scanning microscopy images of cancer cells. A1 – Cell monolayer morphology before EGF 
addition; A2-5 – Morphology of cell monolayer after 6, 14, 28 and 60min exposure to 2nM of EGF, respectively. Prior to 
EGF addition, the cells have been illuminated with 280nm with an irradiance of 1.18 W.m-2 for 45min. 
The exposure time is indeed a very important factor in halting EGFR activation, and internalization, and cellular 
migration, as can be observed in Figure 7. Figure 7 shows the clear influence of 280nm light and exposure time on 
EGFR activation, internalization, filopodia formation and cell migration (Figure 7 A4, B4 and C4). It can be observed 
that the illumination of cells prior to EGF stimulation delays these events, being the effect more evident in cells 
illuminated for a longer period of time.  
Figure 7 - Confocal laser scanning microscopy images of lung carcinoma cells. A1, B1 and C1 – Cell monolayer 
morphology before EGF addition; A4, B4 and C4 – Morphology of cell monolayer after 28min exposure to 2nM of EGF - 
Prior to EGF addition, the cells have been illuminated with 280nm with an irradiance of 0W.m-2 and 1.18 W.m-2 for 
15min and 45min, respectively. 
4. CONCLUSION
The results presented in this paper demonstrated that 280nm illumination of EGFR overexpressing cells prior to their 
stimulation with EGF affects the EGFR/EGF binding ability and, consequently, receptor activation. The 280nm 
illumination time is an important factor, as longer illumination more strongly impairs the activation of EGFR by EGF 
ligand. Filopodia formation and cell migration is significantly delayed when the pulmonary cancer cells are illuminated 
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with 280nm light. Blocking the loss of cellular adhesion and motility is crucial to prevent tumour initiation and 
progression. The new photonic approach has several advantages: it is non-invasive, low intensity of light is used, the 
illumination time is short, no photosensitizer drugs or any other drug are needed. Light can reach deeper tissues through 
the use of optical fibers and/or multiphoton excitation. The biophotonic approach presented in this paper opens the doors 
to the development of a promising anti-cancer therapy.  
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